Mark Shackleton is the Director of Oncology at Alfred Health, a Professor of Oncology at Monash University, Chair of Melanoma and Skin Cancer Trials Ltd, and Co-Director of the Monash Partners Comprehensive Cancer Consortium. After training in medical oncology at the Ludwig Institute in Melbourne, he undertook Ph.D. studies at the Walter and Eliza Hall Institute of Medical Research and post-doctoral work at the University of Michigan, USA. His clinical interests include melanoma and skin cancers, precision oncology, and immunotherapy.
Mark Shackleton is the Director of Oncology at Alfred Health, a Professor of Oncology at Monash University, Chair of Melanoma and Skin Cancer Trials Ltd, and Co-Director of the Monash Partners Comprehensive Cancer Consortium. After training in medical oncology at the Ludwig Institute in Melbourne, he undertook Ph.D. studies at the Walter and Eliza Hall Institute of Medical Research and post-doctoral work at the University of Michigan, USA. His clinical interests include melanoma and skin cancers, precision oncology, and immunotherapy.